一品红(300723.SZ)：子公司获得己酮可可碱缓释片注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. to market Ketone Cocoa Alkaloid Sustained-Release Tablets, which are indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1: Product Approval - The approval includes a drug registration certificate for Ketone Cocoa Alkaloid Sustained-Release Tablets [1] - The tablets are designed to improve blood rheological properties by reducing blood viscosity, thereby enhancing blood flow in patients with chronic peripheral artery disease [1] Group 2: Mechanism of Action - Ketone Cocoa Alkaloid and its metabolites improve blood rheology in a dose-dependent manner, lowering blood viscosity and enhancing red blood cell deformability [1] - The exact mechanism of action for Ketone Cocoa Alkaloid remains unclear, but it is known to enhance the deformability of white blood cells and inhibit the adhesion and activation of neutrophils [1]